Literature DB >> 20008048

Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489.

Alexey Ruzin1, Peter J Petersen, C Hal Jones.   

Abstract

OBJECTIVES: To evaluate development of resistance to the piperacillin/BLI-489 combination.
METHODS: BLI-489 was used at a constant concentration of 4 mg/L. Spontaneous mutation frequency was measured on piperacillin/BLI-489-containing agar plates. Five beta-lactamase-producing strains were exposed to a serial dilution of piperacillin/BLI-489, and the highest concentration allowing growth was used to inoculate subsequent serial passage for 10 days. Mutation stability was monitored in drug-free medium for 10 days.
RESULTS: Escherichia coli (OXA-3, OXA-7, ACT-1, SHV-1 or none), Salmonella enterica serovar Typhimurium (CTX-M-5), Klebsiella pneumoniae (SHV-1 and SHV-5) and Enterobacter cloacae (AmpC) had a spontaneous mutation frequency of < or =1.0 x 10(-9). Two AmpC-producing Pseudomonas aeruginosa strains had a mutation frequency of 6.52 x 10(-6) and 1.0 x 10(-7); a beta-lactamase-negative P. aeruginosa strain had a mutation frequency of 2.68 x 10(-8). The mutant prevention concentration (MPC) was < or =32 mg/L. During serial passages, the MIC increased 64- and 128-fold for S. enterica serovar Typhimurium (CTX-M-5) and E. cloacae (AmpC), respectively, to > or =512 mg/L. The MIC reverted to < or =64 mg/L after serial passages in drug-free medium. The MICs increased only 4-fold for K. pneumoniae (SHV-1 and SHV-5), E. coli (OXA-3) and E. coli (SHV-1).
CONCLUSIONS: Piperacillin/BLI-489 demonstrated a low probability of spontaneous resistance development in vitro for all of the strains tested with the exception of P. aeruginosa. The MPC value for all strains was < or =32 mg/L. Resistance developed during serial passage for two of the five strains tested; however, this resistance phenotype was unstable as MIC values reverted to < or =64 mg/L after propagation in drug-free medium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008048     DOI: 10.1093/jac/dkp435

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Mutant prevention concentrations of four carbapenems against gram-negative rods.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

2.  Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Virna J Schuck; Mary Anne Banevicius; Marie-Eve Beaudoin; Wright W Nichols; M Angela Tanudra; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

3.  Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.

Authors:  Ying Sun; Xueyuan Liao; Zhigang Huang; Yaliu Xie; Yanbin Liu; Cuicui Ma; Boguang Jiang; Li Zhang; Yuhang Yan; Guobo Li; Xingjun Cheng; Qi Yin; Charles Z Ding; Liang Shen; Jian Li; Shuhui Chen; Yuquan Wei; Zhenling Wang; Xiawei Wei
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  Cyclic Boronates Inhibit All Classes of β-Lactamases.

Authors:  Samuel T Cahill; Ricky Cain; David Y Wang; Christopher T Lohans; David W Wareham; Henry P Oswin; Jabril Mohammed; James Spencer; Colin W G Fishwick; Michael A McDonough; Christopher J Schofield; Jürgen Brem
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

5.  Activity of Antimicrobial Peptides and Ciprofloxacin against Pseudomonas aeruginosa Biofilms.

Authors:  Muhammad Yasir; Debarun Dutta; Mark D P Willcox
Journal:  Molecules       Date:  2020-08-24       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.